New cell sources for T cell engineering and adoptive immunotherapy

Maria Themeli, Isabelle Rivière, Michel Sadelain

    Research output: Contribution to journalReview articleAcademicpeer-review

    125 Citations (Scopus)


    The promising clinical results obtained with engineered T cells, including chimeric antigen receptor (CAR) therapy, call for further advancements to facilitate and broaden their applicability. One potentially beneficial innovation is to exploit new T cell sources that reduce the need for autologous cell manufacturing and enable cell transfer across histocompatibility barriers. Here we review emerging T cell engineering approaches that utilize alternative T cell sources, which include virus-specific or T cell receptor-less allogeneic T cells, expanded lymphoid progenitors, and induced pluripotent stem cell (iPSC)-derived T lymphocytes. The latter offer the prospect for true off-the-shelf, genetically enhanced, histocompatible cell therapy products.

    Original languageEnglish
    Pages (from-to)357-66
    Number of pages10
    JournalStem Cell Research
    Issue number4
    Publication statusPublished - 2 Apr 2015


    • Animals
    • Cell Engineering/methods
    • Genetic Engineering
    • Histocompatibility
    • Humans
    • Immunologic Deficiency Syndromes/immunology
    • Immunotherapy, Adoptive
    • Induced Pluripotent Stem Cells/immunology
    • Lymphoid Progenitor Cells/immunology
    • Receptors, Antigen, T-Cell/genetics
    • Recombinant Fusion Proteins/genetics
    • T-Lymphocytes/immunology

    Cite this